Dianthus Therapeutics vs Seres Therapeutics
Dianthus Therapeutics is the larger business, with $2.0m of revenue in fiscal 2025 against $789,000 for Seres Therapeutics (2.6 times as much). Seres Therapeutics kept more of each dollar of sales as profit: a net margin of 721.9% against -7973.3%.
| Latest fiscal year | Dianthus TherapeuticsDNTH, 2025 | Seres TherapeuticsMCRB, 2025 |
|---|---|---|
| Revenue | $2.0m | $789,000 |
| Revenue growth | -67.3% | — |
| Net income | −$162m | $5.7m |
| Operating margin | -8739.3% | — |
| Net margin | -7973.3% | 721.9% |
| Return on equity | -38.4% | 19.6% |
| Free cash flow | −$129m | $865,000 |
| Cash | $51.1m | $45.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 92 | 66 |
| Market value | $4.51bn | $18.0m |
| Price vs our value range | — | Below our value range |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 66 sales | 0 buys, 16 sales |